doxepin has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, S | 1 |
| Wang, X | 1 |
| Hou, Y | 1 |
| Lv, Y | 1 |
| Wang, C | 1 |
| He, H | 1 |
1 other study available for doxepin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Repositioning of histamine H
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Doxepin; Drug | 2021 |